RIPK2 and Alzheimer disease: Consistent with prior reports showing that Avn-C suppresses NF-κB signaling and pro-inflammatory markers in AD models [33], our data further demonstrate that Avn-C significantly downregulated NOD1, RIP2, and p-p65 levels in the hippocampus.